Market Opportunity
Osteoarthritis afflicts more than 32.5 million adults in the United States and 240 million across the globe.
Three million Americans are newly diagnosed every year.
Each year, over 1 million osteoarthritis patients undergo a total knee replacement.
Our goal is to reach patients as early as possible to delay or prevent surgery.
In 2013, the total national arthritis-attributable medical care costs and earnings losses among adults with arthritis were $303.5 billion or 1% of the 2013 US Gross Domestic Product.
Our goal is to provide patients with the ability to resume normal activities and to have normal joint function.
Competitive Edge
Based on the current market for cartilage restoration, Sarcio provides significant advantages over competitors. Steroid/cortisone injections, viscosupplementation (hyaluronic acid) injections, and pain killers promote only temporary relief and do not regrow hyaline cartilage or restore natural joint function. Some new technologies are available, but they are considered experimental and carry a high cost along with variable results, and some require two surgeries.
Sarcio solves many of these issues by providing an off-the-shelf regenerative solution that requires only one, nonsurgical procedure and provides restoration of natural joint function and the regrowth of hyaline cartilage.
Sarcio anticipates providing an easy-to-use solution that will generate reproducible results. This will facilitate an easy decision for patients and providers to adopt the Sarcio treatment and facilitate insurance coverage.